Kaleido Biosciences Inc (NASDAQ:KLDO) reached a new 52-week high during trading on Tuesday . The company traded as high as $18.96 and last traded at $16.86, with a volume of 28235 shares trading hands. The stock had previously closed at $18.10.

A number of equities research analysts have commented on KLDO shares. Chardan Capital started coverage on Kaleido Biosciences in a research note on Tuesday, April 23rd. They issued a “buy” rating and a $17.50 price target for the company. Goldman Sachs Group started coverage on Kaleido Biosciences in a research note on Monday, March 25th. They issued a “buy” rating and a $20.00 price target for the company. Morgan Stanley started coverage on Kaleido Biosciences in a research note on Monday, March 25th. They issued an “overweight” rating and a $17.00 price target for the company. Canaccord Genuity started coverage on Kaleido Biosciences in a research note on Monday, March 25th. They issued a “buy” rating and a $19.00 price target for the company. Finally, JPMorgan Chase & Co. started coverage on Kaleido Biosciences in a research note on Monday, March 25th. They issued a “neutral” rating and a $15.00 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $17.70.

Kaleido Biosciences (NASDAQ:KLDO) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.89). On average, analysts anticipate that Kaleido Biosciences Inc will post -2.78 earnings per share for the current fiscal year.

In other news, major shareholder Ventures Fund V. L.P. Flagship acquired 933,333 shares of Kaleido Biosciences stock in a transaction dated Monday, March 4th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $13,999,995.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael W. Bonney acquired 71,520 shares of Kaleido Biosciences stock in a transaction dated Thursday, February 28th. The stock was purchased at an average price of $13.98 per share, with a total value of $999,849.60. The disclosure for this purchase can be found here.

Large investors have recently made changes to their positions in the company. FMR LLC acquired a new position in shares of Kaleido Biosciences during the first quarter valued at about $25,143,000. BlueCrest Capital Management Ltd bought a new stake in shares of Kaleido Biosciences during the first quarter worth $165,000. Morgan Stanley bought a new stake in shares of Kaleido Biosciences during the first quarter worth $31,000. Arrowgrass Capital Partners US LP bought a new stake in shares of Kaleido Biosciences during the first quarter worth $725,000. Finally, Citigroup Inc. bought a new stake in shares of Kaleido Biosciences during the first quarter worth $35,000. Hedge funds and other institutional investors own 73.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2019/05/23/kaleido-biosciences-kldo-reaches-new-52-week-high-at-18-96.html.

Kaleido Biosciences Company Profile (NASDAQ:KLDO)

Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.

Further Reading: How does a 12b-1 fee affect fund performance?

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.